mircera
roche registration gmbh - metoxi-polietilenglicol epoetina beta - anemia; kidney failure, chronic - preparaciones antianémicas - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.
xeloda 500mg comprimido recubierto
roche farma (peru) s.a. - comprimido recubierto - por comprimido - capecitabina
kadcyla 100 mg polvo para concentrado para solucion para perfusion
roche farma (peru) s.a. - droguerÍa - trastuzumab emtansina - polvo para concentrado para solucion para perfusion - 100 mg - por vial - - trastuzumab emtansine
kadcyla 160 mg polvo para concentrado para solucion para perfusion
roche farma (peru) s.a. - droguerÍa - trastuzumab emtansina - polvo para concentrado para solucion para perfusion - 160 mg - por vial - - trastuzumab emtansine
pulmozyme 2,5mg/2,5ml solucion para inhalacion
roche farma (peru) s.a. - droguerÍa - dornasa alfa - solucion para inhalacion - 2,5mg/2,5ml - por vial 2.50 ml - - dornasa alfa (desoxirribonucleasa)
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - los sueros inmunes e inmunoglobulinas, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. ver secciones 4. 4 y 5.
ronapreve 120 mg/ml + 120 mg/ml solucion inyectable y para perfusion
roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 120mg/ml + 120mg/ml - por vial 11.10 ml - - casirivimab y imdevimab
ronapreve 300 mg + 300 mg solucion inyectable y para perfusion
roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 300mg +300mg - por vial 300.00 mg - - casirivimab y imdevimab
rohipnol roche inyectable parenteral
roche farma, s.a. - flunitrazepam - excipientes: alcohol etilico (etanol),alcohol bencilico,propilenglicol - hipnÓticos y sedantes - derivados de la benzodiazepina - flunitrazepam
roche cardiac poc troponin t.
productos roche q.f.s.a. -